< Back to previous page
Researcher
Mark Waer
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Department of Microbiology, Immunology and Transplantation (Department)
Member
From1 Oct 2016 → Today - Tracheal Transplantation (Lab)
Member
From1 Oct 2005 → 30 Sep 2016 - Nephrology and Renal Transplantation Research Group (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
1 - 10 of 11
- Immunosuppressive effects of a CD4 receptor down-modulator: in vitro study of the signal peptide-dependent ER translocation inhibitor cyclotriazadisulfonamide (CADA)From1 Oct 2014 → 26 Sep 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Proteomics analysis for the identification of candidate protective proteins against sepsisFrom1 Oct 2014 → 16 Nov 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- "BD FACS Verse" Flow Cytometer.From16 Apr 2012 → 25 Oct 2018Funding: Hercules - Small and Medium size research infrastructure
- Identification of new immunomodulating targets and agents for B lymphocytesFrom1 Oct 2011 → 7 Jun 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- How does 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) act on immune cells during autoimmunity?From1 Dec 2010 → 30 Sep 2013Funding: BOF - Doctoral projects
- FACS Cell sorter (FACSAriaII), central to the establishment of a K.U.Leuven FACS core Facility.From22 Jul 2010 → 21 Jan 2017Funding: Hercules - Small and Medium size research infrastructure
- Recipient-mediated antileukemic effects after allogeneic hematopoietic stem cell transplantation: studies in mice.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
- Molecular modeling, synthesis and biological evaluation of human amino-acyltRNA synthetase inhibitors as immunosuppressive agents.From1 Jan 2009 → 31 Dec 2014Funding: FWO research project
- Beckman Coulter Gallios flowcytometer.From20 Oct 2008 → 19 Apr 2015Funding: Hercules - Small and Medium size research infrastructure
- The marginal zone B cel in concordant xenograft rejection: critical help signals in the T cel-independent type II xenoantibody response and possible targets for xeno-immunosuppression.From1 Oct 2008 → 30 Sep 2013Funding: FWO fellowships
Publications
1 - 10 of 62
- Synthesis of mizoribine prodrugs and their in vivo evaluation as immunosuppressive agents(2023)
Authors: Ling-Jie Gao, Steven De Jonghe, Mark Waer, Piet Herdewyn
- Establishment of operational tolerance to sustain antitumor immunotherapy(2022)
Authors: Mark Waer, Ben Sprangers
Pages: 568 - 577 - Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes(2021)
Authors: Elisa Claeys, Eva Pauwels, Stephanie Humblet-Baron, Dominique Schols, Mark Waer, Ben Sprangers, Kurt Vermeire
- Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment(2021)
Authors: Nana Dang, Mark Waer, Ben Sprangers
Pages: 151 - 162 - Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts(2021)
Authors: Nana Dang, Mark Waer, Ben Sprangers
Pages: 60 - 72 - Donor Lymphocyte-Derived Natural Killer Cells Control MHC Class I-Negative Melanoma(2020)
Authors: Nana Dang, Mark Waer, Ben Sprangers
Pages: 756 - 768 - Improved Anti-Tumour Adaptive Immunity Can Overcome the Melanoma Immunosuppressive Tumour Microenvironment(2019)
Authors: Nana Dang, Mark Waer, Ben Sprangers
- Immunosuppressive effects of a CD4 receptor down-modulator: in vitro study of the signal peptide-dependent ER translocation inhibitor cyclotriazadisulfonamide (CADA)(2019)
Authors: Elisa Claeys, Kurt Vermeire, Dominique Schols, Mark Waer
- Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation(2019)
Authors: Nana Dang, Xavier Sagaert, Mark Waer, Ben Sprangers
Pages: 2709 - 2721 - Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo(2018)
Authors: Ling-Jie Gao, Piet Herdewyn, Yuan Lin, Thierry Louat, Mark Waer
Pages: 6705 - 6723
Patents
1 - 8 of 8
- Novel prodrugs of mizoribine (Inventor)
- Autoimmune and inflammatory disorder therapy (Inventor)
- Novel prodrugs of mizoribine (Inventor)
- Purine analogues and their use as immunosuppressive agents (Inventor)
- Autoimmune and inflammatory disorder therapy (Inventor)
- Thiazolopyrimidine modulators as immunosuppressive agents (Inventor)
- Thiazolopyrimidine modulators as immunosuppressive agents (Inventor)
- THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS (Inventor)